You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePimecrolimus
Accession NumberDB00337  (APRD01182)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Pimecrolimus is an immunomodulating agent used in the treatment of atopic dermatitis (eczema). It is currently available as a topical cream, once marketed by Novartis, (however Galderma will be promoting the molecule in Canada in early 2007) under the trade name Elidel. [Wikipedia]

Structure
Thumb
Synonyms
33-Epi-chloro-33-desoxyascomycin
Pimecrolimus
Pimecrolimusum
External Identifiers
  • ASM 981
  • SDZ ASM 981
  • SDZ ASM-981
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Elidelcream10 mg/gtopicalValeant Pharmaceuticals North America LLC2001-12-02Not applicableUs
Elidelcream1 %topicalValeant Canada Lp Valeant Canada S.E.C.2003-03-24Not applicableCanada
Elidelcream10 mg/gtopicalPhysicians Total Care, Inc.2003-10-30Not applicableUs
Elidelcream10 mg/gtopicalValeant Pharmaceuticals North America LLC2001-12-02Not applicableUs
Elidelcream10 mg/gtopicalValeant Pharmaceuticals North America LLC2001-12-02Not applicableUs
Elidelcream10 mg/gtopicalValeant Pharmaceuticals North America LLC2001-12-02Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AregenMeda Pharm
RizanEsteve
Brand mixturesNot Available
SaltsNot Available
Categories
UNII7KYV510875
CAS number137071-32-0
WeightAverage: 810.46
Monoisotopic: 809.4480897
Chemical FormulaC43H68ClNO11
InChI KeyKASDHRXLYQOAKZ-XDSKOBMDSA-N
InChI
InChI=1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31-,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1
IUPAC Name
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(1E)-1-[(1R,3R,4S)-4-chloro-3-methoxycyclohexyl]prop-1-en-2-yl]-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0⁴,⁹]octacos-18-ene-2,3,10,16-tetrone
SMILES
[H][C@]1(CC[[email protected]](Cl)[C@@H](C1)OC)\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([[email protected]](C[[email protected]]2C)OC)[[email protected]](C[C@@H](C)C\C(C)=C\[C@@H](CC)C(=O)C[[email protected]](O)[[email protected]]1C)OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as macrolide lactams. These are cyclic polyketides containing both a cyclic amide and a cyclic ester group.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassMacrolide lactams
Sub ClassNot Available
Direct ParentMacrolide lactams
Alternative Parents
Substituents
  • Macrolide lactam
  • Alpha-amino acid ester
  • Macrolide
  • Alpha-amino acid or derivatives
  • Cyclohexyl halide
  • Oxane
  • Piperidine
  • Tertiary carboxylic acid amide
  • Carboxamide group
  • Carboxylic acid ester
  • Hemiacetal
  • Ketone
  • Lactam
  • Lactone
  • Secondary alcohol
  • Cyclic ketone
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Azacycle
  • Oxacycle
  • Carboxylic acid derivative
  • Dialkyl ether
  • Ether
  • Alcohol
  • Alkyl chloride
  • Alkyl halide
  • Organic nitrogen compound
  • Organic oxygen compound
  • Organochloride
  • Organonitrogen compound
  • Organooxygen compound
  • Organic oxide
  • Hydrocarbon derivative
  • Carbonyl group
  • Organohalogen compound
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor treatment of mild to moderate atopic dermatitis.
PharmacodynamicsPimecrolimus is a chemical that is used to treat atopic dermatitis (eczema). Atopic dermatitis is a skin condition characterized by redness, itching, scaling and inflammation of the skin. The cause of atopic dermatitis is not known; however, scientists believe that it may be due to activation of the immune system by various environmental or emotional triggers. Scientists do not know exactly how pimecrolimus reduces the manifestations of atopic dermatitis, but pimecrolimus reduces the action of T-cells and mast cells which are part of the immune system and contribute to responses of the immune system. Pimecrolimus prevents the activation of T-cells by blocking the effects of chemicals (cytokines) released by the body that stimulate T-cells. Pimecrolimus also reduces the ability of mast cells to release chemicals that promote inflammation.
Mechanism of actionPimecrolimus binds with high affinity to macrophilin-12 (FKBP-12) and inhibits the calcium-dependent phosphatase, calcineurin. As a consequence, it inhibits T cell activation by blocking the transcription of early cytokines. In particular, pimecrolimus inhibits at nanomolar concentrations Interleukin-2 and interferon gamma (Th1-type) and Interleukin-4 and Interleukin-10 (Th2-type) cytokine synthesis in human T cells. Also, pimecrolimus prevents the release of inflammatory cytokines and mediators from mast cells in vitro after stimulation by antigen/lgE.
Related Articles
AbsorptionBecause of the low systemic absorption of pimecrolimus following topical application the calculation of standard pharmacokinetic measures such as AUC, Cmax, half-life, etc. cannot be reliably done.
Volume of distributionNot Available
Protein binding74%-87% (in vitro, bound to plasma proteins)
Metabolism

No drug metabolism was observed in human skin in vitro. Oral administration yielded metabolites produced from O-demethylation and oxygenation reactions.

Route of elimination80% of the drug is excreted in the feces.
Half lifeNot Available
ClearanceNot Available
ToxicitySide effects include burning sensation, irritation, pruritus, erythema, and skin infections, at the application site.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6208
Blood Brain Barrier-0.9554
Caco-2 permeable-0.5764
P-glycoprotein substrateSubstrate0.8064
P-glycoprotein inhibitor IInhibitor0.8064
P-glycoprotein inhibitor IIInhibitor0.7014
Renal organic cation transporterNon-inhibitor0.8556
CYP450 2C9 substrateNon-substrate0.9117
CYP450 2D6 substrateNon-substrate0.8856
CYP450 3A4 substrateSubstrate0.7519
CYP450 1A2 substrateNon-inhibitor0.8678
CYP450 2C9 inhibitorNon-inhibitor0.8671
CYP450 2D6 inhibitorNon-inhibitor0.9026
CYP450 2C19 inhibitorNon-inhibitor0.8248
CYP450 3A4 inhibitorNon-inhibitor0.8672
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9326
Ames testNon AMES toxic0.6495
CarcinogenicityNon-carcinogens0.9183
BiodegradationNot ready biodegradable0.9937
Rat acute toxicity2.6919 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9787
hERG inhibition (predictor II)Non-inhibitor0.6886
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
Creamtopical1 %
Creamtopical10 mg/g
Prices
Unit descriptionCostUnit
Elidel 100 Gram Tube 1% 100 gm Tube315.76USD tube
Elidel 60 Gram Tube 1% 60 gm Tube200.05USD tube
Elidel 30 Gram Tube 1% 30 gm Tube101.44USD tube
Elidel 1% cream3.21USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2200966 No2006-12-192015-10-26Canada
US5912238 Yes1996-12-152016-12-15Us
US6352998 Yes1996-04-262016-04-26Us
US6423722 Yes1998-12-262018-12-26Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00152 mg/mLALOGPS
logP4.36ALOGPS
logP6.81ChemAxon
logS-5.7ALOGPS
pKa (Strongest Acidic)9.96ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area158.13 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity214.03 m3·mol-1ChemAxon
Polarizability87.79 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Viktor Gyollai, Csaba Szabo, “Methods of preparing pimecrolimus.” U.S. Patent US20060142564, issued June 29, 2006.

US20060142564
General References
  1. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G: A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999 Aug;141(2):264-73. [PubMed:10468798 ]
External Links
ATC CodesD11AH02
AHFS Codes
  • 84:92.00
PDB EntriesNot Available
FDA labelDownload (230 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with 2-Methoxyethanol.
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.
AbataceptThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Abatacept.
AbciximabPimecrolimus may increase the anticoagulant activities of Abciximab.
abetimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with abetimus.
ABR-215757The risk or severity of adverse effects can be increased when Pimecrolimus is combined with ABR-215757.
AcebutololPimecrolimus may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Aceclofenac.
AcenocoumarolPimecrolimus may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Acetylsalicylic acid.
AdalimumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Adalimumab.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Pimecrolimus.
AfelimomabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Afelimomab.
AlefaceptThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alefacept.
AlemtuzumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alemtuzumab.
Alendronic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alendronic acid.
alicaforsenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with alicaforsen.
AliskirenPimecrolimus may decrease the antihypertensive activities of Aliskiren.
AlprenololPimecrolimus may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Pimecrolimus.
AltretamineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Altretamine.
AmikacinPimecrolimus may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmiloridePimecrolimus may decrease the antihypertensive activities of Amiloride.
AmiodaroneThe metabolism of Pimecrolimus can be decreased when combined with Amiodarone.
AmsacrineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Amsacrine.
AnakinraThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anakinra.
AncrodPimecrolimus may increase the anticoagulant activities of Ancrod.
Anti-thymocyte Globulin (Rabbit)The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anti-thymocyte Globulin (Rabbit).
AntipyrineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Antipyrine.
Antithrombin III humanPimecrolimus may increase the anticoagulant activities of Antithrombin III human.
ApixabanPimecrolimus may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Apremilast.
AprepitantThe serum concentration of Pimecrolimus can be increased when it is combined with Aprepitant.
ArdeparinPimecrolimus may increase the anticoagulant activities of Ardeparin.
ArgatrobanPimecrolimus may increase the anticoagulant activities of Argatroban.
ArotinololPimecrolimus may decrease the antihypertensive activities of Arotinolol.
AtazanavirThe metabolism of Pimecrolimus can be decreased when combined with Atazanavir.
AtenololPimecrolimus may decrease the antihypertensive activities of Atenolol.
AtomoxetineThe metabolism of Pimecrolimus can be decreased when combined with Atomoxetine.
AzacitidineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azacitidine.
AzapropazoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azapropazone.
AzathioprineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azathioprine.
AzelastineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Pimecrolimus.
BalsalazidePimecrolimus may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Pimecrolimus.
BasiliximabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Basiliximab.
BecaplerminPimecrolimus may increase the anticoagulant activities of Becaplermin.
BefunololPimecrolimus may decrease the antihypertensive activities of Befunolol.
BelataceptThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Belatacept.
BelimumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Belimumab.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Pimecrolimus.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Pimecrolimus.
BenoxaprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benoxaprofen.
BetamethasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Betamethasone.
BetaxololPimecrolimus may decrease the antihypertensive activities of Betaxolol.
BevantololPimecrolimus may decrease the antihypertensive activities of Bevantolol.
BexaroteneThe serum concentration of Pimecrolimus can be decreased when it is combined with Bexarotene.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Pimecrolimus.
BisoprololPimecrolimus may decrease the antihypertensive activities of Bisoprolol.
BivalirudinPimecrolimus may increase the anticoagulant activities of Bivalirudin.
BleomycinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bleomycin.
BlinatumomabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Blinatumomab.
BoceprevirThe metabolism of Pimecrolimus can be decreased when combined with Boceprevir.
BopindololPimecrolimus may decrease the antihypertensive activities of Bopindolol.
BortezomibThe metabolism of Pimecrolimus can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Pimecrolimus can be decreased when it is combined with Bosentan.
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Brentuximab vedotin.
BriakinumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Briakinumab.
BromfenacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bromfenac.
BudesonideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Budesonide.
BufuralolPimecrolimus may decrease the antihypertensive activities of Bufuralol.
BumetanidePimecrolimus may decrease the diuretic activities of Bumetanide.
BupranololPimecrolimus may decrease the antihypertensive activities of Bupranolol.
BusulfanThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Busulfan.
CabazitaxelThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cabazitaxel.
CanakinumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Canakinumab.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Pimecrolimus.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pimecrolimus.
CapecitabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Pimecrolimus.
CarbamazepineThe metabolism of Pimecrolimus can be increased when combined with Carbamazepine.
CarboplatinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carboplatin.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Pimecrolimus.
CarmustineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carmustine.
CarprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carprofen.
CarteololPimecrolimus may decrease the antihypertensive activities of Carteolol.
CarvedilolPimecrolimus may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Celecoxib.
CeliprololPimecrolimus may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Pimecrolimus can be increased when it is combined with Ceritinib.
Certolizumab pegolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Certolizumab pegol.
CertoparinPimecrolimus may increase the anticoagulant activities of Certoparin.
ChlorambucilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Chlorambucil.
ChloroquineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Chloroquine.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pimecrolimus.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Pimecrolimus.
CholestyramineCholestyramine can cause a decrease in the absorption of Pimecrolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pimecrolimus.
CisplatinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cisplatin.
Citric AcidPimecrolimus may increase the anticoagulant activities of Citric Acid.
CladribineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine.
ClarithromycinThe metabolism of Pimecrolimus can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Pimecrolimus can be decreased when combined with Clemastine.
ClodronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clodronate.
ClofarabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clofarabine.
ClonixinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Pimecrolimus.
ClotrimazoleThe metabolism of Pimecrolimus can be decreased when combined with Clotrimazole.
CobicistatThe metabolism of Pimecrolimus can be decreased when combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Pimecrolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Pimecrolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.
ConivaptanThe serum concentration of Pimecrolimus can be increased when it is combined with Conivaptan.
CorticotropinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Corticotropin.
Cortisone acetateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cortisone acetate.
CrizotinibThe metabolism of Pimecrolimus can be decreased when combined with Crizotinib.
CyclophosphamideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclophosphamide.
CyclosporineThe metabolism of Pimecrolimus can be decreased when combined with Cyclosporine.
CyclosporinePimecrolimus may increase the nephrotoxic activities of Cyclosporine.
CytarabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cytarabine.
D-LimoneneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with D-Limonene.
Dabigatran etexilatePimecrolimus may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Pimecrolimus can be decreased when it is combined with Dabrafenib.
DacarbazineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dacarbazine.
DaclizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daclizumab.
DactinomycinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dactinomycin.
DalteparinPimecrolimus may increase the anticoagulant activities of Dalteparin.
DanaparoidPimecrolimus may increase the anticoagulant activities of Danaparoid.
DarunavirThe metabolism of Pimecrolimus can be decreased when combined with Darunavir.
DasatinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dasatinib.
DasatinibThe serum concentration of Pimecrolimus can be increased when it is combined with Dasatinib.
DaunorubicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daunorubicin.
DeferasiroxThe serum concentration of Pimecrolimus can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Deferasirox.
DelavirdineThe metabolism of Pimecrolimus can be decreased when combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pimecrolimus.
DesirudinPimecrolimus may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desmopressin.
DexamethasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexamethasone.
DexamethasoneThe serum concentration of Pimecrolimus can be decreased when it is combined with Dexamethasone.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Pimecrolimus.
DextranPimecrolimus may increase the anticoagulant activities of Dextran.
Dextran 40Pimecrolimus may increase the anticoagulant activities of Dextran 40.
Dextran 70Pimecrolimus may increase the anticoagulant activities of Dextran 70.
Dextran 75Pimecrolimus may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Diclofenac.
DicoumarolPimecrolimus may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Diflunisal.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Pimecrolimus.
DihydroergotamineThe metabolism of Pimecrolimus can be decreased when combined with Dihydroergotamine.
DihydrostreptomycinPimecrolimus may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DiltiazemThe metabolism of Pimecrolimus can be decreased when combined with Diltiazem.
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dimethyl fumarate.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Pimecrolimus.
DinutuximabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dinutuximab.
DocetaxelThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Docetaxel.
DoxorubicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Doxorubicin.
DoxycyclineThe metabolism of Pimecrolimus can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Pimecrolimus can be decreased when combined with Dronedarone.
DrospirenonePimecrolimus may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Droxicam.
EculizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Eculizumab.
Edetic AcidPimecrolimus may increase the anticoagulant activities of Edetic Acid.
EdoxabanPimecrolimus may increase the anticoagulant activities of Edoxaban.
EfalizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Efalizumab.
EfavirenzThe serum concentration of Pimecrolimus can be decreased when it is combined with Efavirenz.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Pimecrolimus.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pimecrolimus.
EnoxaparinPimecrolimus may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Pimecrolimus can be decreased when it is combined with Enzalutamide.
EpirizoleThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Epirizole.
EpirubicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Epirubicin.
EplerenonePimecrolimus may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Pimecrolimus.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pimecrolimus.
ErythromycinThe metabolism of Pimecrolimus can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Pimecrolimus can be decreased when it is combined with Eslicarbazepine acetate.
EsmololPimecrolimus may decrease the antihypertensive activities of Esmolol.
EstramustineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Estramustine.
Etacrynic acidPimecrolimus may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etanercept.
Ethyl biscoumacetatePimecrolimus may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etofenamate.
EtoposideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etoposide.
EtoricoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etoricoxib.
EtravirineThe serum concentration of Pimecrolimus can be decreased when it is combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Evening primrose oil.
EverolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Everolimus.
exisulindThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fenoprofen.
FingolimodThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Pimecrolimus.
FloxuridineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Floxuridine.
FluconazoleThe metabolism of Pimecrolimus can be decreased when combined with Fluconazole.
FludarabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fludarabine.
FludrocortisoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fludrocortisone.
FlunixinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flunixin.
FluorouracilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluorouracil.
FlurbiprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flurbiprofen.
FluvoxamineThe metabolism of Pimecrolimus can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Pimecrolimus.
Fondaparinux sodiumPimecrolimus may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Pimecrolimus.
FosamprenavirThe metabolism of Pimecrolimus can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Pimecrolimus can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pimecrolimus.
FosphenytoinThe metabolism of Pimecrolimus can be increased when combined with Fosphenytoin.
FramycetinPimecrolimus may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemidePimecrolimus may decrease the diuretic activities of Furosemide.
Fusidic AcidThe serum concentration of Pimecrolimus can be increased when it is combined with Fusidic Acid.
Gallium nitrateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gallium nitrate.
GemcitabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemcitabine.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Pimecrolimus.
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemtuzumab ozogamicin.
GentamicinPimecrolimus may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
Glatiramer AcetateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Glatiramer Acetate.
GlimepirideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Glimepiride.
GolimumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Golimumab.
HaloperidolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Haloperidol.
HeparinPimecrolimus may increase the anticoagulant activities of Heparin.
HirulogPimecrolimus may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Pimecrolimus is combined with HMPL-004.
HydralazinePimecrolimus may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pimecrolimus.
HydrocortisoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hydrocortisone.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Pimecrolimus.
HydroxyureaThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hydroxyurea.
Hygromycin BPimecrolimus may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibandronate.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibrutinib.
IbuprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Icatibant.
IdarubicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Idarubicin.
IdelalisibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Idelalisib.
IdelalisibThe serum concentration of Pimecrolimus can be increased when it is combined with Idelalisib.
IfosfamideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ifosfamide.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Pimecrolimus.
ImatinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Imatinib.
ImatinibThe metabolism of Pimecrolimus can be decreased when combined with Imatinib.
ImiquimodThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Imiquimod.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Pimecrolimus.
IndenololPimecrolimus may decrease the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Pimecrolimus can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pimecrolimus.
IndoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Indoprofen.
InfliximabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Infliximab.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pimecrolimus.
IrinotecanThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Irinotecan.
IsavuconazoniumThe metabolism of Pimecrolimus can be decreased when combined with Isavuconazonium.
IsoxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Isoxicam.
IsradipineThe metabolism of Pimecrolimus can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Pimecrolimus can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Pimecrolimus can be increased when it is combined with Ivacaftor.
KanamycinPimecrolimus may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Kebuzone.
KetoconazoleThe metabolism of Pimecrolimus can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pimecrolimus.
L-PhenylalanineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with L-Phenylalanine.
LabetalolPimecrolimus may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Leflunomide.
LenalidomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lenalidomide.
LepirudinPimecrolimus may increase the anticoagulant activities of Lepirudin.
LevobunololPimecrolimus may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pimecrolimus.
LithiumThe serum concentration of Lithium can be increased when it is combined with Pimecrolimus.
LomustineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lomustine.
LopinavirThe metabolism of Pimecrolimus can be decreased when combined with Lopinavir.
LornoxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Pimecrolimus.
LovastatinThe metabolism of Pimecrolimus can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Pimecrolimus.
LuliconazoleThe serum concentration of Pimecrolimus can be increased when it is combined with Luliconazole.
LumiracoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pimecrolimus.
MechlorethamineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mechlorethamine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Meloxicam.
MelphalanThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Melphalan.
MepolizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mepolizumab.
MercaptopurineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mercaptopurine.
MesalazinePimecrolimus may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Pimecrolimus.
MetamizoleThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Metamizole.
MethotrexateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methotrexate.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pimecrolimus.
MethylprednisoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methylprednisolone.
MetipranololPimecrolimus may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Pimecrolimus.
MetoprololPimecrolimus may decrease the antihypertensive activities of Metoprolol.
MetrizamidePimecrolimus may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MifepristoneThe metabolism of Pimecrolimus can be decreased when combined with Mifepristone.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Pimecrolimus.
MitomycinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mitomycin.
MitotaneThe serum concentration of Pimecrolimus can be decreased when it is combined with Mitotane.
MitoxantroneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mitoxantrone.
ModafinilThe serum concentration of Pimecrolimus can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Pimecrolimus.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Pimecrolimus.
MuromonabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Muromonab.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nabumetone.
NadololPimecrolimus may decrease the antihypertensive activities of Nadolol.
NadroparinPimecrolimus may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Pimecrolimus can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Naproxen.
NatalizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Natalizumab.
NCX 4016The risk or severity of adverse effects can be increased when Pimecrolimus is combined with NCX 4016.
NefazodoneThe metabolism of Pimecrolimus can be decreased when combined with Nefazodone.
NelarabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nelarabine.
NelfinavirThe metabolism of Pimecrolimus can be decreased when combined with Nelfinavir.
NeomycinPimecrolimus may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nepafenac.
NetilmicinPimecrolimus may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NetupitantThe serum concentration of Pimecrolimus can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Pimecrolimus can be decreased when combined with Nevirapine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Niflumic Acid.
NilotinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nilotinib.
NilotinibThe metabolism of Pimecrolimus can be decreased when combined with Nilotinib.
NimesulideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nimesulide.
ObinutuzumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Obinutuzumab.
OlaparibThe metabolism of Pimecrolimus can be decreased when combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pimecrolimus.
OlopatadineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Olopatadine.
OlsalazinePimecrolimus may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Pimecrolimus.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Pimecrolimus.
OrgoteinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Orgotein.
OsimertinibThe serum concentration of Pimecrolimus can be increased when it is combined with Osimertinib.
OtamixabanPimecrolimus may increase the anticoagulant activities of Otamixaban.
OxaliplatinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxaliplatin.
OxaprozinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxaprozin.
OxprenololPimecrolimus may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxyphenbutazone.
PaclitaxelThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Paclitaxel.
PalbociclibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Palbociclib.
PalbociclibThe serum concentration of Pimecrolimus can be increased when it is combined with Palbociclib.
PamidronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pamidronate.
PanobinostatThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Panobinostat.
ParecoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Parecoxib.
ParomomycinPimecrolimus may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PazopanibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pazopanib.
PegaspargaseThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pegaspargase.
PemetrexedThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pemetrexed.
PenbutololPimecrolimus may decrease the antihypertensive activities of Penbutolol.
PentobarbitalThe metabolism of Pimecrolimus can be increased when combined with Pentobarbital.
Pentosan PolysulfatePimecrolimus may increase the anticoagulant activities of Pentosan Polysulfate.
PentostatinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pentostatin.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Pimecrolimus.
PhenindionePimecrolimus may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Pimecrolimus can be increased when combined with Phenobarbital.
PhenprocoumonPimecrolimus may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Phenylbutazone.
PhenytoinThe metabolism of Pimecrolimus can be increased when combined with Phenytoin.
PindololPimecrolimus may decrease the antihypertensive activities of Pindolol.
PiretanidePimecrolimus may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Piroxicam.
PlicamycinPimecrolimus may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Pimecrolimus.
PomalidomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pomalidomide.
PosaconazoleThe metabolism of Pimecrolimus can be decreased when combined with Posaconazole.
PractololPimecrolimus may decrease the antihypertensive activities of Practolol.
PralatrexateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pralatrexate.
PrednisoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednisolone.
PrednisoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednisone.
PrimidoneThe metabolism of Pimecrolimus can be increased when combined with Primidone.
ProbenecidThe serum concentration of Pimecrolimus can be increased when it is combined with Probenecid.
ProcarbazineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Procarbazine.
PropacetamolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Propacetamol.
PropranololPimecrolimus may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Pimecrolimus.
Protein CPimecrolimus may increase the anticoagulant activities of Protein C.
ProtocatechualdehydePimecrolimus may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Pimecrolimus is combined with PTC299.
PuromycinPimecrolimus may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Pimecrolimus.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Pimecrolimus.
Rabies vaccineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rabies vaccine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Pimecrolimus.
RanolazineThe metabolism of Pimecrolimus can be decreased when combined with Ranolazine.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pimecrolimus.
ResveratrolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Resveratrol.
ReviparinPimecrolimus may increase the anticoagulant activities of Reviparin.
RibostamycinPimecrolimus may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifabutinThe metabolism of Pimecrolimus can be increased when combined with Rifabutin.
RifampicinThe metabolism of Pimecrolimus can be increased when combined with Rifampicin.
RifapentineThe metabolism of Pimecrolimus can be increased when combined with Rifapentine.
RilonaceptThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rilonacept.
RisedronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Risedronate.
RitonavirThe metabolism of Pimecrolimus can be decreased when combined with Ritonavir.
RituximabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rituximab.
RivaroxabanPimecrolimus may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rofecoxib.
RoflumilastRoflumilast may increase the immunosuppressive activities of Pimecrolimus.
RuxolitinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ruxolitinib.
SalicylamideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Pimecrolimus.
SaquinavirThe metabolism of Pimecrolimus can be decreased when combined with Saquinavir.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Pimecrolimus.
SecukinumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Secukinumab.
SeocalcitolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Seocalcitol.
SeratrodastThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Seratrodast.
SildenafilThe metabolism of Pimecrolimus can be decreased when combined with Sildenafil.
SiltuximabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Siltuximab.
SiltuximabThe serum concentration of Pimecrolimus can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Pimecrolimus can be increased when it is combined with Simeprevir.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pimecrolimus.
SirolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sirolimus.
SorafenibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sorafenib.
SotalolPimecrolimus may decrease the antihypertensive activities of Sotalol.
SpectinomycinPimecrolimus may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Pimecrolimus.
SpironolactonePimecrolimus may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Pimecrolimus is combined with SRT501.
St. John's WortThe serum concentration of Pimecrolimus can be decreased when it is combined with St. John's Wort.
SteproninThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Stepronin.
StiripentolThe serum concentration of Pimecrolimus can be increased when it is combined with Stiripentol.
StreptomycinPimecrolimus may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Streptozocin.
SulfasalazinePimecrolimus may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pimecrolimus.
SulfisoxazoleThe metabolism of Pimecrolimus can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sulindac.
SulodexidePimecrolimus may increase the anticoagulant activities of Sulodexide.
SunitinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sunitinib.
SuprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Suprofen.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Pimecrolimus.
TacrolimusPimecrolimus may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Pimecrolimus.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Pimecrolimus.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Technetium Tc-99m Medronate.
TelaprevirThe metabolism of Pimecrolimus can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Pimecrolimus can be decreased when combined with Telithromycin.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pimecrolimus.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Pimecrolimus.
TemozolomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Temozolomide.
TemsirolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Temsirolimus.
TeniposideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Teniposide.
TenofovirThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Teriflunomide.
ThalidomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Thalidomide.
ThiotepaThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Thiotepa.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tiaprofenic acid.
TiclopidineThe metabolism of Pimecrolimus can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tiludronate.
TimololPimecrolimus may decrease the antihypertensive activities of Timolol.
TioguanineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tioguanine.
TobramycinPimecrolimus may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TocilizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tocilizumab.
TocilizumabThe serum concentration of Pimecrolimus can be decreased when it is combined with Tocilizumab.
TofacitinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tofacitinib.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tolmetin.
TopotecanThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Topotecan.
TorasemidePimecrolimus may decrease the diuretic activities of Torasemide.
TositumomabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tositumomab.
TrabectedinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trabectedin.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pimecrolimus.
TranilastThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tranilast.
TrastuzumabTrastuzumab may increase the neutropenic activities of Pimecrolimus.
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trastuzumab emtansine.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Pimecrolimus.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Pimecrolimus.
TretinoinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tretinoin.
TriamcinoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Triamcinolone.
TriamterenePimecrolimus may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Pimecrolimus.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trisalicylate-choline.
UstekinumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ustekinumab.
ValdecoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Valdecoxib.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Pimecrolimus.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Pimecrolimus.
VedolizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vedolizumab.
VenlafaxineThe metabolism of Pimecrolimus can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Pimecrolimus can be decreased when combined with Verapamil.
VilanterolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vilanterol.
VinblastineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vinblastine.
VincristineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vincristine.
VindesineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vindesine.
VinorelbineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vinorelbine.
VoriconazoleThe metabolism of Pimecrolimus can be decreased when combined with Voriconazole.
WarfarinPimecrolimus may increase the anticoagulant activities of Warfarin.
XimelagatranPimecrolimus may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zileuton.
ZiprasidoneThe metabolism of Pimecrolimus can be decreased when combined with Ziprasidone.
Zoledronic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Tfiiic-class transcription factor binding
Specific Function:
Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activ...
Gene Name:
MTOR
Uniprot ID:
P42345
Molecular Weight:
288889.05 Da
References
  1. Reitamo S, Remitz A, Kyllonen H, Saarikko J: Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol. 2002;3(6):381-8. [PubMed:12113647 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
potentiator
General Function:
Type i transforming growth factor beta receptor binding
Specific Function:
Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. Recruites SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. May modulate the RYR1 calcium channel activity. PPIases accelerate the folding of proteins....
Gene Name:
FKBP1A
Uniprot ID:
P62942
Molecular Weight:
11950.665 Da
References
  1. Reitamo S, Remitz A, Kyllonen H, Saarikko J: Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol. 2002;3(6):381-8. [PubMed:12113647 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zollinger M, Waldmeier F, Hartmann S, Zenke G, Zimmerlin AG, Glaenzel U, Baldeck JP, Schweitzer A, Berthier S, Moenius T, Grassberger MA: Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab Dispos. 2006 May;34(5):765-74. Epub 2006 Feb 7. [PubMed:16467136 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 31, 2016 03:28